{"id":"NCT01218997","sponsor":"Alkermes, Inc.","briefTitle":"ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®)","officialTitle":"A Randomized, Open Label, Long-Term, Multi-Center Study of the Safety of Medisorb® Naltrexone","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-08","primaryCompletion":"2005-03","completion":"2005-03","firstPosted":"2010-10-13","resultsPosted":"2010-12-13","lastUpdate":"2011-01-04"},"enrollment":436,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Alcoholism"],"interventions":[{"type":"DRUG","name":"Medisorb naltrexone 380 mg","otherNames":["VIVITROL® 380 mg","Naltrexone for extended-release injectable suspension"]},{"type":"DRUG","name":"Oral naltrexone 50 mg","otherNames":["Revia®"]}],"arms":[{"label":"Medisorb naltrexone 380 mg (VIVITROL)","type":"EXPERIMENTAL"},{"label":"Oral naltrexone 50 mg","type":"ACTIVE_COMPARATOR"}],"summary":"This was a Phase 3 multicenter randomized, open-label, safety study assessing the safety of repeat doses of Medisorb® naltrexone 380 mg (VIVITROL®) administered for up to 1 year to adults with alcohol and/or opioid dependence as defined by Diagnostic and Statistical Manual of Mental Health Disorders (DSM-IV) criteria. Eligible subjects were randomized in a 6:1 ratio to receive 1 of the following regimens: a single intramuscular (IM) injection of VIVITROL administered once every 4 weeks or oral naltrexone 50 mg administered daily.","primaryOutcome":{"measure":"Number of Subjects Reporting at Least 1 Treatment-emergent Adverse Event (TEAE) While on Study","timeFrame":"up to 1 year","effectByArm":[{"arm":"Medisorb Naltrexone 380 mg (VIVITROL)","deltaMin":336,"sd":null},{"arm":"Oral Naltrexone 50 mg","deltaMin":53,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":13},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":49,"n":371},"commonTop":["Nausea","Headache NOS","Nasopharyngitis","Insomnia","Upper respiratory tract infection NOS"]}}